<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="other"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Indian J Ophthalmol</journal-id><journal-id journal-id-type="publisher-id">Indian Journal of Ophthalmology</journal-id><journal-title-group><journal-title>Indian Journal of Ophthalmology</journal-title></journal-title-group><issn pub-type="ppub">0301-4738</issn><issn pub-type="epub">1998-3689</issn><publisher><publisher-name>Medknow Publications</publisher-name><publisher-loc>India</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">18417819</article-id><article-id pub-id-type="pmc">2636116</article-id><article-id pub-id-type="publisher-id">IndianJOphthalmol_2008_56_3_197_40357</article-id><article-id pub-id-type="pmid">18417819 </article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Transconjunctival penetration of mitomycin C</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Velpandian</surname><given-names>T</given-names></name><degrees>MD</degrees></contrib><contrib contrib-type="author"><name><surname>Sihota</surname><given-names>Ramanjit</given-names></name><degrees>MD, FRCO</degrees></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Sinha</surname><given-names>Ankur</given-names></name><degrees>MD</degrees></contrib><contrib contrib-type="author"><name><surname>Gupta</surname><given-names>Viney</given-names></name><degrees>MD</degrees></contrib></contrib-group><aff>Dr. Rajendra Prasad Centre for Ophthalmic Sciences, All India Institute of Medical Sciences, New Delhi, India</aff><author-notes><corresp id="cor1">Correspondence to Dr. Ankur Sinha, Dr. Rajendra Prasad Centre forOphthalmic Sciences, All India Institute of Medical Science, AnsariNagar, New Delhi - 110 029, India. Email: <email>drankursinha@yahoo.co.uk</email></corresp></author-notes><pub-date pub-type="ppub"><season>May-Jun</season><year>2008</year></pub-date><volume>56</volume><issue>3</issue><fpage>197</fpage><lpage>201</lpage><history><date date-type="received"><day>21</day><month>3</month><year>2007</year></date><date date-type="accepted"><day>17</day><month>12</month><year>2007</year></date></history><permissions><copyright-statement>Copyright: &#x000a9; Indian Journal of Ophthalmology</copyright-statement><copyright-year>2008</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc-sa/3.0"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><sec><title>Aims:</title><p>The study was performed to estimate transconjunctival penetration of mitomycin C (MMC) to Tenon&#x02032;stissue following application over the intact conjunctiva before routine trabeculectomy.</p></sec><sec><title>Settings and Design:</title><p>Institution-based case series.</p></sec><sec><title>Materials and Methods: </title><p>In 41 eyes of 41 patients, MMC (0.4 mg/ml for 3 min) was applied over the intactconjunctiva before beginning trabeculectomy. Tenon&#x02032;s capsule directly beneath the site of application wasexcised during trabeculectomy and was homogenized, centrifuged and MMC concentrations were analyzedusing high-performance liquid chromatography (HPLC).</p></sec><sec><title>Statistical Analysis Used:</title><p>Statistical analysis was performed using  stata0  8.0 version software (STATACorporation, Houston, TX, USA). In this study, <italic>P</italic> -values less than 0.05 were considered as statisticallysignificant.</p></sec><sec><title>Results:</title><p>The average weight of the sample of Tenon&#x02032;s tissue excised was 5.51 &#x000b1; 4.42 mg (range:0.9-17.1) and the average estimated MMC concentration found to be present in Tenon&#x02032;s tissue using HPLC was18.67 &#x000b1; 32.36 &#x000d7; 10<sup>&#x02212;6</sup> moles/kg of the tissue (range: 0.38-197.05 x 10<sup>&#x02212;6</sup> ). In 36 ofthe 41 patients (87.80%), the MMC concentration reached above 2 x 10<sup>&#x02212;6</sup> moles/kg of the tissue concentrationrequired to inhibit human conjunctival fibroblasts.</p></sec><sec><title>Conclusions:</title><p>Mitomycin C does permeate into the subconjunctival tissue after supraconjunctival applicationfor 3 min. Application of MMC over the conjunctiva may be a useful alternative to subconjunctival orsubscleral application during routine trabeculectomy and as an adjunct for failing blebs.</p></sec></abstract><kwd-group><kwd>High-performance liquid chromatography estimation</kwd><kwd>mitomycin C</kwd><kwd>supraconjunctival mitomycin</kwd><kwd>topical application</kwd></kwd-group></article-meta></front><body><p>Cytostatic substances, such as mitomycin C (MMC), have beenused intraoperatively as an adjunct in trabeculectomies. Theanti-proliferative agents (MMC and 5-florouracil) haveimproved the outcome of glaucoma-filtering surgeries.<xref ref-type="bibr" rid="ref1">1</xref>-<xref ref-type="bibr" rid="ref6">6</xref> This may be either due to the cytostatic effects manifestingas delayed wound healing resulting in prolonged enhancedfiltration or possibly a direct toxic effect on the epithelium ofciliary body or both.<xref ref-type="bibr" rid="ref4">4</xref>,<xref ref-type="bibr" rid="ref7">7</xref></p><p>Factors that influence the anti-fibroblastic effects of MMCare the concentration used, area of application, duration ofapplication and material of sponge used.<xref ref-type="bibr" rid="ref8">8</xref> The best mode in termsof concentration, duration, place, and number of applicationsis still not known<xref ref-type="bibr" rid="ref9">9</xref> and rationale behind single intraoperativeapplication has also been questioned.<xref ref-type="bibr" rid="ref10">10</xref> There have beenreports of topical application of MMC after trabeculectomyfor post-operative pharmacological modulation.<xref ref-type="bibr" rid="ref4">4</xref>,<xref ref-type="bibr" rid="ref6">6</xref>,<xref ref-type="bibr" rid="ref11">11</xref> Thesereports have shown MMC application in the form of topicaldrops<xref ref-type="bibr" rid="ref6">6</xref> and surface application<xref ref-type="bibr" rid="ref4">4</xref>,<xref ref-type="bibr" rid="ref11">11</xref> to be an effective alternativeto single intraoperative application. However, there has beenno study in the literature estimating the concentration of MMCin Tenon&#x02032;s tissue after surface application of the drug over theintact conjunctiva. The aim of the study was to estimate theconcentration of MMC in Tenon&#x02032;s tissue after single topicalapplication of the MMC.</p><sec sec-type="materials|methods"><title>Materials and Methods</title><p>After taking clearance from the Institutional Review Board,this pilot study was conducted. The study included patientswho were scheduled for a standard trabeculectomy fromFebruary 2005 to December 2005. The study was carried outwithin the tenets of the Declaration of Helsinki. Only eyes ofpatients not achieving target intraocular pressure (IOP) onmaximum tolerable medical therapy (at least three topicalmedications, which included 0.5% timolol, 0.15% brimonidine,2% pilocarpine, 0.005% latanoprost or 0.03% bimatoprost alongwith oral acetazolamide and/or syrup glycerol and intravenousmannitol) were included in this study. The patients withhistory of prior glaucoma surgery, conjunctival congestionwere excluded from the study. After informed consent (seeAppendix) and explaining the procedure in detail, a peribulbarblock from (6 ml of 2% xylocaine and 4 ml of 0.5% sensoricaine)was given through the skin. All the trabeculectomies wereperformed by two surgeons (R.S. and V.G) using a limbal-basedconjunctival flap as described by Cairns.<xref ref-type="bibr" rid="ref12">12</xref> Whole dry weck cellsponge (Supersoak sponges; Madhu Instruments, New Delhi,India) were soaked (till it maximally absorbed MMC) withfreshly prepared 0.4 mg/ml of MMC and these were then placeddirectly over the intact bulbar conjunctiva at the proposed siteof trabeculectomy for 3 min. The drug was thoroughly washedout of the palpebral sac with 10 ml of the Ringer lactate solution.A superior rectus bridle suture was then passed and 8-10 mmhigh limbus-based flap was raised. A small piece of Tenon&#x02032;stissue was excised just below the area of application and high-performance liquid chromatography (HPLC) estimation of theMMC in sample was done using the procedure described below.The samples were coded and subjected for MMC estimation inthe department of ocular pharmacology.</p><p>Estimation of MMC from the tissue samples was performedas per the method reported earlier with minor modification.<xref ref-type="bibr" rid="ref13">13</xref>Briefly, the tissues were weighed immediately along with thepre-weighed microcentrifuge tubes upon their arrival. Methanol(HPLC grade) was added at the volume of 200 &#x000b5;l and preservedat &#x02212;70&#x000b0;C till analysis. On the day of analysis, the samples werehomogenized in cold condition using hand-held microcentrifugetube homogenizer to avoid the evaporation of methanol. Sampleswere then centrifuged at 5000  &#x000d7; <italic>g</italic> for 10 min. The supernatantunderwent HPLC quantification, thermo <italic>surveyor</italic> HPLC systemwas used. The mobile phase containing phosphate buffer (pH6.5)and acetonitrile in the ratio of 8:2 v/v was used. It was pumpedat the flow rate of 1 ml/min and the analytical separation wasachieved by C8-Kromosil (250 x 4.6 mm, 5 &#x000b5;) column (FlexitJour Laboratories Pvt Ltd, Pune, Maharashtra, India). TheUV detection was achieved at 365 nm and peak purity wasperformed over a wavelength range of 200-400 nm using thecustom-made library of photodiode array option [<xref ref-type="fig" rid="F1">Fig. 1</xref>].</p><p>Under the above conditions, MMC was eluted at theretention time of 6.52 min. The limit of detection of MMC usingthe above method is 0.427 x 10<sup>&#x02212;6</sup> moles/kg of the tissue. Theweight of the tissue samples varied from 0.9 to 17.1 mg with amean of 5.5 + 4.42 mg (median 4.2).</p><p>Mean concentration and the range of concentrations obtainedfrom the tissues sent were evaluated. The concentration ofMMC obtained from the tissue was correlated with the weightof the tissue and the age of the patients. Statistical analysiswas performed using stata 8.0 version software (STATACorporation). In this study, <italic>P</italic> -values less than 0.05 wereconsidered as statistically significant.</p></sec><sec><title>Results</title><p>A total of 41 eyes of 41 patients were included in the study. Ofthe 41 patients, there were 28 males and 13 females. The meanage of the patients was 45.63 &#x000b1; 18.27 years (range: 3-77 years).The mean pre-operative IOP recorded was 26.61 &#x000b1; 3.52 mmHg(on maximum tolerable medical therapy). Of the 41 patients,22 were diagnosed to have chronic primary angle closureglaucoma, nine had primary open angle glaucoma and 10had other forms of glaucoma [congenital (1), angle recession(1), Axenfeld-Reigers anomaly (2), neovascular glaucomawithout significant conjunctival hyperemia and inflammationcontrolled on steroids (2), secondary glaucoma associatedwith adherent leukoma (1), operated pars plana vitrectomy(1), Sturge-Weber syndrome (1) and aphakia (1)].</p><p>The average weight of the sample of Tenon&#x02032;s tissue excisedwas 5.51 &#x000b1; 4.42 mg (median 4.2 mg with a range 0.9-17.1) andthe average estimated MMC concentration was 18.67 &#x000b1; 32.3 &#x000d7;10<sup>&#x02212;6</sup> moles/kg of the tissue (range: 0.38-197.05 &#x000d7; 10<sup>&#x02212;6</sup>). In 36 ofthe 41 patients (87.80%), the MMC concentration reached above2  &#x000d7; 10<sup>&#x02212;6</sup> moles/kg of the tissue (concentration required to inhibithuman conjunctival fibroblasts<xref ref-type="bibr" rid="ref14">14</xref>). On statistical analysis, thecorrelation between the weight of the sample and the MMCconcentration (<italic>P</italic> = 0.2, <italic>r</italic> = 0.18) and the age of the patient andthe MMC concentration detected (<italic>P</italic> = 0.3, <italic>r</italic> = 0.16) in the samplewas not found to be statistically significant. The results havebeen summarized in <xref ref-type="table" rid="T1">Table 1</xref> and Figs. <xref ref-type="fig" rid="F2">2</xref> and <xref ref-type="fig" rid="F3">3</xref>.</p><p>Of the 41 eyes included in the study, shallow anteriorchamber (AC) was noted in five cases. Single procedure of ACreformation (under sterile conditions, sterile air was injected inthe AC with the help of 26-G needle under topical anesthesiawith 0.5% proparacaine) was sufficient to manage four of thefive cases with shallow AC. In one case, after two proceduresof AC reformation, bleb revision was done to manage shallowAC. In no case was bleb leak, thin bleb, persistent hypotony,choroidal detachment, hypotonic maculopathy or cornealepithelial toxicity noticed in the first post-operative month.</p></sec><sec><title>Discussion</title><p>Mitomycin C is an antibiotic, alkylating agent, which acts bybinding to DNA and inhibits cell mitosis and interferes withRNA transcription and protein synthesis<xref ref-type="bibr" rid="ref7">7</xref>,<xref ref-type="bibr" rid="ref15">15</xref> and isfound to inhibit proliferation of cultured human Tenon&#x02032;s fibroblasts aftera brief exposure of 1-5 min.<xref ref-type="bibr" rid="ref16">16</xref></p><p>Mitomycin C is now used intraoperatively in theglaucomatous eyes having a high risk of surgical failure.However, in some eyes, the need for anti-fibrotic agent is feltonly after surgery when subconjunctival scarring or encystmentof the bleb is seen. MMC drops have been applied but havebeen fraught with problems.<xref ref-type="bibr" rid="ref6">6</xref></p><p>Wound healing is a complex process and there are manyinter-individual variations apart from variations among races.Even in the present study, there was a wide variation of theamount of MMC detected in different tissue samples for thesame amount of concentration applied topically; this could beaccounted for by the differences in conjunctival and Tenon&#x02032;sthickness in different individuals.</p><p>Pharmacokinetics of MMC has been studied and it hasbeen shown experimentally on human donor eyes thatMMC penetrates the sclera easily and irrigation reduces theconcentration only in the superficial layers.<xref ref-type="bibr" rid="ref17">17</xref> It is further shownthat during trabeculectomy in human eyes, the diffusion ofMMC to the deeper layers continues even after the end ofexposure to the soaked sponge.<xref ref-type="bibr" rid="ref18">18</xref> These experiments furtherreveal that after 1 min application of 0.2 mg/ml of MMC, themaximum concentrations on the inner side of the sclera mayreach 0.01-2 &#x000b5;g/ml depending upon the duration of exposure.<xref ref-type="bibr" rid="ref18">18</xref>Jampel has shown that MMC when applied in the concentrationof 0.4 mg/ml for a period of 5 min almost totally stops theproliferation of cultured human fibroblasts (90% inhibition).<xref ref-type="bibr" rid="ref16">16</xref>Morphologic proof of toxic effects of MMC on non-pigmentedepithelium of ciliary body following episcleral application<xref ref-type="bibr" rid="ref7">7</xref>,<xref ref-type="bibr" rid="ref19">19</xref> suggest a role of ciliary hypo-secretion as a cause of persistenthypotony.</p><p>The present study conclusively demonstrated that MMCpenetrates the conjunctival epithelium and is found in amean concentration of 18.67 &#x000b1; 32.36 x 10<sup>&#x02212;6</sup> moles/kg of thetissue (range: 0.38-197.05 x 10<sup>&#x02212;6</sup> ) in Tenon&#x02032;s tissue. It has beenexperimentally shown (<italic>in vitro</italic>) that an MMC concentration of2 x 10<sup>&#x02212;6</sup> M (moles/liter) is required to inhibit the proliferation offibroblasts. In our study, concentration higher than the abovementioned was estimated in 36 of the 41 patients (87.80%)in whom MMC was applied over the intact conjunctiva.Furthermore, supraconjunctival application may reducethe amount of drug diffusion through the sclera as thedrug is applied over the conjunctiva and there are barriersof conjunctiva and Tenon&#x02032;s capsule in addition to sclera,thereby reducing the chances of ciliary epithelium toxicitymanifesting as prolonged hypotony and other complications.The concentration is represented in moles/kg of tissue sinceestimation of water content in such a small quantity of humantissue was not possible for the molar calculation for each andevery sample.</p><p>Post-operative use of MMC in the form of drops (0.3 mg/ml)has been shown to be effective in terms of halting and reversingearly subconjunctival fibrosis.<xref ref-type="bibr" rid="ref6">6</xref> Corneal epithelial toxicity,however, has been seen with the use of topical drops.</p><p>In a study by Mietz <italic>et al</italic>., post-operative surface applicationversus intraoperative application of MMC was compared.<xref ref-type="bibr" rid="ref11">11</xref>It was found that the hypotony as a transient phenomenonoccurred in 36% cases in post-operative application groupas compared to 77% cases in the intraoperative applicationgroup. The mean IOP at final visit was 16.0 &#x000b1; 2.7 (9-20) inpost-operative application group and 12.5 &#x000b1; 7.1 (4-32) in theintraoperative application group. None of the cases in thepost-operative group reported ocular discomfort or cornealerosions. In our study, transient hypotony requiring ACreformation or bleb revision was noted in 5 of the 41 (12.20%) cases, no cases of bleb leak, thin bleb, persistent hypotony,choroidal detachment, hypotonic maculopathy or cornealepithelial toxicity was noticed in the immediate post-operativeperiod.</p><p>It is well proven that anti-metabolites, when used withneedle revision enhance the success of failing blebs.<xref ref-type="bibr" rid="ref20">20</xref>During these procedures subconjunctival injection of 5 FUare given in the bleb area. On noticing the early signs ofbleb failures such as bleb injection, bleb vascularization orlarge ropy vessels<xref ref-type="bibr" rid="ref21">21</xref> over the bleb area, MMC may be appliedsupraconjunctivally. Our study shows that MMC freelypenetrates the conjunctiva and would probably inhibit theproliferation of fibroblasts underneath. Supraconjunctivalapplication of MMC may provide a less invasive alternativeto subconjunctival application, especially when used alongwith bleb revision. We believe that in cases showing earlysigns of failing bleb,<xref ref-type="bibr" rid="ref21">21</xref> one can opt for post-operative surfaceapplication of MMC.<xref ref-type="bibr" rid="ref11">11</xref></p><p>In our study, there was large variation in the amount oftissue harvested and the concentration of MMC achievedin Tenon&#x02032;s tissue; however, in most of the cases (80.80%),the MMC concentration reached above 2 x 10<sup>&#x02212;6</sup> moles/kg ofthe tissue. Despite the limitations of the study, in that therewas no standardization of the amount of tissue excised foranalysis and only a single concentration of 0.4 mg/ml for afixed duration of time (3 min) was studied, the quantitativeinformation regarding the transconjunctival penetration of supraconjunctival MMC is clear.</p><p>This pilot study conclusively proves that significantconcentrations of MMC can be achieved by a singlesupraconjunctival application of 0.4 mg/ml. This mode ofapplication may be a less invasive and theoretically a saferalternative to subconjunctival application of MMC, especiallyfor revival of a failing bleb and provide an effective penetrationof anti-metabolite at the required site.</p></sec></body><back><fn-group><fn><p>Presentation at meeting: Organization: SEAGIG; Place: Chennai; Date:December 1-3, 2006</p></fn><fn><p>Source of Support: Nil</p></fn><fn><p>Conflict of Interest: None declared</p></fn></fn-group><ref-list><ref id="ref1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Palmer</surname><given-names>SS</given-names></name></person-group><article-title>Mitomycin as adjunct chemotherapy with trabeculectomy</article-title><source>Ophthalmology</source><year>1991</year><volume>98</volume><fpage>317</fpage><lpage>21</lpage><pub-id pub-id-type="pmid">2023752</pub-id></element-citation></ref><ref id="ref2"><label>2</label><element-citation publication-type="journal"><collab>The Fluorouracil Filtering Surgery Study Group</collab><article-title>Three year follow-up of the fluorouracil filtering surgery study</article-title><source>Am J Ophthalmol</source><year>1993</year><volume>115</volume><fpage>82</fpage><lpage>92</lpage><pub-id pub-id-type="pmid">8420383</pub-id></element-citation></ref><ref id="ref3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kupin</surname><given-names>TH</given-names></name><name><surname>Juzych</surname><given-names>MS</given-names></name><name><surname>Shin</surname><given-names>DH</given-names></name><name><surname>Khatana</surname><given-names>AK</given-names></name><name><surname>Olivier</surname><given-names>MM</given-names></name></person-group><article-title>Adjunctive mitomycin C in primary trabeculectomy in phakic eyes</article-title><source>Am J Ophthalmol</source><year>1995</year><volume>119</volume><fpage>30</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">7825687</pub-id></element-citation></ref><ref id="ref4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mietz</surname><given-names>H</given-names></name><name><surname>Jacobi</surname><given-names>PC</given-names></name><name><surname>Krieglstein</surname><given-names>GK</given-names></name></person-group><article-title>Intraoperative episcleral versus postoperative topical application of mitomycin-C for trabeculectomies</article-title><source>Ophthalmology</source><year>2002</year><volume>109</volume><fpage>1343</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">12093661</pub-id></element-citation></ref><ref id="ref5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>WuDunn</surname><given-names>D</given-names></name><name><surname>Cantor</surname><given-names>LB</given-names></name><name><surname>Palanca-Capistrano</surname><given-names>AM</given-names></name><name><surname>Hoop</surname><given-names>J</given-names></name><name><surname>Alvi</surname><given-names>NP</given-names></name><name><surname>Finley</surname><given-names>C</given-names></name><etal/></person-group><article-title>A prospective randomized trial comparing intraoperative 5-fluorouracil vs mitomycin C in primarytrabeculectomy</article-title><source>Am J Ophthalmol</source><year>2002</year><volume>134</volume><fpage>521</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">12383808</pub-id></element-citation></ref><ref id="ref6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sihota</surname><given-names>R</given-names></name><name><surname>Sood</surname><given-names>NN</given-names></name><name><surname>Agarwal</surname><given-names>HC</given-names></name></person-group><article-title>Mitomycin C drops in the post-operative pharmacological modulation of trabeculectomies</article-title><source>Ann Ophthalmol</source><year>1997</year><volume>26</volume><fpage>362</fpage><lpage>6</lpage></element-citation></ref><ref id="ref7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nuyts</surname><given-names>RM</given-names></name><name><surname>Felten</surname><given-names>PC</given-names></name><name><surname>Pels</surname><given-names>E</given-names></name><name><surname>Langerhorst</surname><given-names>CT</given-names></name><name><surname>Geijssen</surname><given-names>HC</given-names></name><name><surname>Grossniklaus</surname><given-names>HE</given-names></name><etal/></person-group><article-title>Histopathologic effects of mitomycin C after trabeculectomy in human glaucomatous eyes with persistenthypotony</article-title><source>Am J Ophthalmol</source><year>1994</year><volume>118</volume><fpage>225</fpage><lpage>37</lpage><pub-id pub-id-type="pmid">8053469</pub-id></element-citation></ref><ref id="ref8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>YY</given-names></name><name><surname>Sexton</surname><given-names>RM</given-names></name><name><surname>Shin</surname><given-names>DH</given-names></name><name><surname>Kim</surname><given-names>C</given-names></name><name><surname>Ginde</surname><given-names>SA</given-names></name><name><surname>Ren</surname><given-names>J</given-names></name><etal/></person-group><article-title>Outcomes of primary phakic trabeculectomies without versus with 0.5- to 1-minute versus 3- to 5-minute mitomycinC</article-title><source>Am J Ophthalmol</source><year>1998</year><volume>126</volume><fpage>755</fpage><lpage>62</lpage><pub-id pub-id-type="pmid">9859998</pub-id></element-citation></ref><ref id="ref9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Esser</surname><given-names>J</given-names></name><name><surname>Esser</surname><given-names>P</given-names></name><name><surname>Mietz</surname><given-names>H</given-names></name><name><surname>Hueber</surname><given-names>A</given-names></name><name><surname>Kociok</surname><given-names>N</given-names></name><name><surname>Schraermeyer</surname><given-names>U</given-names></name><etal/></person-group><article-title>Multidrug resistance-associated proteins in glaucoma surgery</article-title><source>Graefes Arch Clin Exp Ophthalmol</source><year>2000</year><volume>238</volume><fpage>727</fpage><lpage>32</lpage><pub-id pub-id-type="pmid">11045339</pub-id></element-citation></ref><ref id="ref10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khaw</surname><given-names>PT</given-names></name><name><surname>Sherwood</surname><given-names>MB</given-names></name><name><surname>MacKay</surname><given-names>LD</given-names></name><name><surname>Rossi</surname><given-names>MJ</given-names></name><name><surname>Schultz</surname><given-names>G</given-names></name></person-group><article-title>Five minutes treatments with fluorouracil, floxuridine and mitomycin have long term effects on human Tenon&#x02032;scapsule fibroblasts</article-title><source>Arch Ophthalmol</source><year>1992</year><volume>110</volume><fpage>1150</fpage><lpage>4</lpage><pub-id pub-id-type="pmid">1386726</pub-id></element-citation></ref><ref id="ref11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mietz</surname><given-names>H</given-names></name><name><surname>Jacobi</surname><given-names>PC</given-names></name><name><surname>Krieglstein</surname><given-names>GK</given-names></name></person-group><article-title>Postoperative application of Mitomycin for Trabeculectomies</article-title><source>Arch Ophthalmol</source><year>2000</year><volume>118</volume><fpage>1341</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">11030815</pub-id></element-citation></ref><ref id="ref12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cairns</surname><given-names>JE</given-names></name></person-group><article-title>Trabeculectomy: Preliminary report of a new method</article-title><source>Am J Ophthalmol</source><year>1968</year><volume>66</volume><fpage>673</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">4891876</pub-id></element-citation></ref><ref id="ref13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Velpandian</surname><given-names>T</given-names></name><name><surname>Saluja</surname><given-names>V</given-names></name><name><surname>Ravi</surname><given-names>AK</given-names></name><name><surname>Kumari</surname><given-names>SS</given-names></name><name><surname>Mathur</surname><given-names>R</given-names></name><name><surname>Ranjan</surname><given-names>N</given-names></name><etal/></person-group><article-title>Evaluation of the stability of extemporaneously prepared ophthalmic formulation of mitomycin C</article-title><source>J Ocul Pharmacol Ther</source><year>2005</year><volume>21</volume><fpage>217</fpage><lpage>22</lpage><pub-id pub-id-type="pmid">15969639</pub-id></element-citation></ref><ref id="ref14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>DA</given-names></name><name><surname>Lee</surname><given-names>TC</given-names></name><name><surname>Corres</surname><given-names>AE</given-names></name><name><surname>Kirada</surname><given-names>S</given-names></name></person-group><article-title>Effects of mifhramycin, mitomycin, daunorubicin and bleomycin on human subconjunctival fibroblast attachment andproliferation</article-title><source>Invest Ophthalmol Vis Sci</source><year>1990</year><volume>31</volume><fpage>2136</fpage><lpage>44</lpage><pub-id pub-id-type="pmid">2211010</pub-id></element-citation></ref><ref id="ref15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zacharia</surname><given-names>PT</given-names></name><name><surname>Deppermann</surname><given-names>SR</given-names></name><name><surname>Schuman</surname><given-names>JS</given-names></name></person-group><article-title>Ocular hypotony after trabeculectomy with Mitomycin-C</article-title><source>Am J Ophthalmol</source><year>1993</year><volume>116</volume><fpage>314</fpage><lpage>26</lpage><pub-id pub-id-type="pmid">8357056</pub-id></element-citation></ref><ref id="ref16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jampel</surname><given-names>HD</given-names></name></person-group><article-title>Effect of brief exposure to mitomycin C on viability and proliferation of cultured human Tenon&#x02032;sfibroblasts</article-title><source>Ophthalmology</source><year>1992</year><volume>99</volume><fpage>1471</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">1407982</pub-id></element-citation></ref><ref id="ref17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vass</surname><given-names>C</given-names></name><name><surname>Georgopoulos</surname><given-names>M</given-names></name><name><surname>el Menyawi</surname><given-names>I</given-names></name><name><surname>Radda</surname><given-names>S</given-names></name><name><surname>Nimmerrichter</surname><given-names>P</given-names></name></person-group><article-title>Intrascleral concentration vs depth profile of mitomycin-C after episcleral application: Impact of applied concentrationand volume of mitomycin-C solution</article-title><source>Exp Eye Res</source><year>2000</year><volume>70</volume><fpage>571</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">10870515</pub-id></element-citation></ref><ref id="ref18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Georgopoulos</surname><given-names>M</given-names></name><name><surname>Vass</surname><given-names>C</given-names></name><name><surname>El Menyawi</surname><given-names>I</given-names></name><name><surname>Radda</surname><given-names>S</given-names></name><name><surname>Graninger</surname><given-names>W</given-names></name><name><surname>Menapace</surname><given-names>R</given-names></name></person-group><article-title>In vitro diffusion of mitomycin-C into human sclera after episcleral application: Impact of diffusiontime</article-title><source>Exp Eye Res</source><year>2000</year><volume>71</volume><fpage>453</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">11040080</pub-id></element-citation></ref><ref id="ref19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schraermeyer</surname><given-names>U</given-names></name><name><surname>Diestelhorst</surname><given-names>M</given-names></name><name><surname>Bieker</surname><given-names>A</given-names></name><name><surname>Theisohn</surname><given-names>M</given-names></name><name><surname>Mietz</surname><given-names>H</given-names></name><name><surname>Ustundag</surname><given-names>C</given-names></name><etal/></person-group><article-title>Morphologic proof of the toxicity of mitomycin C on the ciliary body in relation to different applicationmethods</article-title><source>Graefes Arch Clin Exp Ophthalmol</source><year>1999</year><volume>237</volume><fpage>593</fpage><lpage>600</lpage><pub-id pub-id-type="pmid">10424310</pub-id></element-citation></ref><ref id="ref20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Broadway</surname><given-names>DC</given-names></name><name><surname>Bloom</surname><given-names>PA</given-names></name><name><surname>Bunce</surname><given-names>C</given-names></name><name><surname>Thiagarajan</surname><given-names>M</given-names></name><name><surname>Khaw</surname><given-names>PT</given-names></name></person-group><article-title>Needle revision of failing and failed trabeculectomy blebs with adjunctive 5-fluorouracil: Survivalanalysis</article-title><source>Ophthalmology</source><year>2004</year><volume>111</volume><fpage>665</fpage><lpage>73</lpage><pub-id pub-id-type="pmid">15051196</pub-id></element-citation></ref><ref id="ref21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shingleton</surname><given-names>BJ</given-names></name></person-group><article-title>Management of the failing glaucoma filter</article-title><source>Ophthalmic Surg Lasers</source><year>1996</year><volume>27</volume><fpage>445</fpage><lpage>51</lpage><pub-id pub-id-type="pmid">8782258</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="F1" position="float"><label>Figure 1</label><caption><p>Chromatogram of a patient's tissue sample showing mitomycin C (peak eluting at the retention time of 6.52 min)</p></caption><alt-text>Figure 1</alt-text><graphic xlink:href="IndianJOphthalmol-56-197-g001"/></fig><fig id="F2" position="float"><label>Figure 2</label><caption><p>Distribution of age of the patients included in the study</p></caption><alt-text>Figure 2</alt-text><graphic xlink:href="IndianJOphthalmol-56-197-g003"/></fig><fig id="F3" position="float"><label>Figure 3</label><caption><p>Age versus average weight of Tenon's tissue</p></caption><alt-text>Figure 3</alt-text><graphic xlink:href="IndianJOphthalmol-56-197-g004"/></fig><table-wrap id="T1" position="float"><label>Table 1</label><caption><p>The weight (average &#x000b1; SD) of Tenon's tissue obtained and concentration (average &#x000b1; SD) of mitomycin C (MMC)estimated</p></caption><alt-text>Table 1</alt-text><graphic xlink:href="IndianJOphthalmol-56-197-g002"/></table-wrap></floats-group></article>